Christopher J Fraser
Overview
Explore the profile of Christopher J Fraser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
258
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thompson M, Staatz C, Fraser C, Hennig S, Lawson R
Ther Drug Monit
. 2025 Feb;
PMID: 39964198
Background: Noncompartmental analysis (NCA) and model-based method (MBM) can be used to estimate the cumulative area under the concentration-time curve (AUCcum) during therapeutic drug monitoring. Understanding predictive differences among these...
2.
3.
Groll A, Schulte J, Antmen A, Fraser C, Teal V, Haber B, et al.
Pediatr Infect Dis J
. 2024 Jan;
43(3):203-208.
PMID: 38241643
Introduction: Letermovir is a cytomegalovirus (CMV) terminase complex inhibitor approved for prophylaxis of CMV infection and disease in adult CMV-seropositive allogeneic hematopoietic cell transplantation (allo-HCT) recipients (R+). We report pharmacokinetics...
4.
Lawson R, Staatz C, Fraser C, Ramachandran S, Teague L, Mitchell R, et al.
CPT Pharmacometrics Syst Pharmacol
. 2022 May;
11(8):1002-1017.
PMID: 35611997
This study aimed to characterize the population pharmacokinetics (PK) of busulfan focusing on how busulfan clearance (CL) changes over time during once-daily administration and assess different methods for measuring busulfan...
5.
Furlong E, Kotecha R, Conyers R, OBrien T, Hansford J, Super L, et al.
Med J Aust
. 2022 Feb;
216(6):312-319.
PMID: 35201615
Introduction: The Australian Technical Advisory Group on Immunisation and New Zealand Ministry of Health recommend all children aged ≥ 5 years receive either of the two mRNA COVID-19 vaccines: Comirnaty...
6.
Lawson R, Paterson L, Fraser C, Hennig S
Cancer Chemother Pharmacol
. 2021 May;
88(3):379-391.
PMID: 34021809
Aim: To assess the ability of model-based personalised dosing tools to estimate busulfan exposure (i) in comparison to clinically used intensive sampling exposure estimation procedure, (ii) using limited sampling strategies...
7.
Vavassori S, Chou J, Faletti L, Haunerdinger V, Opitz L, Joset P, et al.
J Allergy Clin Immunol
. 2021 Apr;
148(2):381-393.
PMID: 33872655
Background: Recognition of viral nucleic acids is one of the primary triggers for a type I interferon-mediated antiviral immune response. Inborn errors of type I interferon immunity can be associated...
8.
Lawson R, Staatz C, Fraser C, Hennig S
Clin Pharmacokinet
. 2020 Oct;
60(1):17-51.
PMID: 33128207
We aimed to review the pharmacokinetics (PK) of intravenous busulfan in paediatric patients, identify covariate factors influencing exposure, investigate evidence of changes in PK behaviour over time, and correlate exposure...
9.
Koyyalamudi S, Kuzhiumparambil U, Nath C, Byrne J, Fraser C, OBrien T, et al.
J Chromatogr Sci
. 2015 Oct;
54(3):326-33.
PMID: 26433392
Treosulfan (l-threitol-1,4-di-methanesulfonate) is a prodrug of a bifunctional alkylating agent that is being used increasingly in pediatric bone marrow transplantation regimens. The activation pathway is a complex reaction, which consists...
10.
Pinkerton R, Wills R, Coory M, Fraser C
Med J Aust
. 2010 Aug;
193(4):217-21.
PMID: 20712542
Objectives: To examine 5-year survival from haematological malignancies in children, adolescents and young adults in Australia and determine if there has been any improvement in survival for the older age...